Evidence map›Paper›PMID 38005331›Full record

ArticleMolecules (Basel, Switzerland)2023

Norcantharidin-Encapsulated C60-Modified Nanomicelles: A Potential Approach to Mitigate Cytotoxicity in Renal Cells and Simultaneously Enhance Anti-Tumor Activity in Hepatocellular Carcinoma Cells.

Zhongpeng Ding, Beihua Xu, Huimin Zhang, Zhenyu Wang, Luying Sun, Mengjie Tang, Meihong Ding, Ting Zhang, Senlin Shi

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Norcantharidin/CuMaterials today. Bio · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zhongpeng DingCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
Beihua XuCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
Huimin ZhangCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
Zhenyu WangCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
Luying SunCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
Mengjie TangCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
Meihong DingCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
Ting ZhangCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.
Senlin ShiCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311400, China.ORCID 0000-0003-3608-3496
Zhejiang Chinese Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective of this study was to examine the preparation process of DSPE-PEG-C60/NCTD micelles and assess the impact of fullerenol (C60)-modified micelles on the nephrotoxicity and antitumor activity of NCTD.

methodThe micelles containing NCTD were prepared using the ultrasonic method and subsequently optimized and characterized. The cytotoxicity of micelles loaded with NCTD was assessed using the CCK-8 method on human hepatoma cell lines HepG2 and BEL-7402, as well as normal cell lines HK-2 and L02. Acridine orange/ethidium bromide (AO/EB) double staining and flow cytometry were employed to assess the impact of NCTD-loaded micelles on the apoptosis of the HK-2 cells and the HepG2 cells. Additionally, JC-1 fluorescence was utilized to quantify the alterations in mitochondrial membrane potential. The generation of reactive oxygen species (ROS) following micelle treatment was determined through 2',7'-dichlorofluorescein diacetate (DCFDA) staining.

resultsThe particle size distribution of the DSPE-PEG-C60/NCTD micelles was determined to be 91.57 nm (PDI = 0.231). The zeta potential of the micelles was found to be -13.8 mV. The encapsulation efficiency was measured to be 91.9%. The in vitro release behavior of the micelles followed the Higuchi equation. Cellular experiments demonstrated a notable decrease in the toxicity of the C60-modified micelles against the HK-2 cells, accompanied by an augmented inhibitory effect on cancer cells. Compared to the free NCTD group, the DSPE-PEG-C60 micelles exhibited a decreased apoptosis rate (12%) for the HK-2 cell line, lower than the apoptosis rate observed in the NCTD group (36%) at an NCTD concentration of 75 μM. The rate of apoptosis in the HepG2 cells exhibited a significant increase (49%), surpassing the apoptosis rate observed in the NCTD group (24%) at a concentration of 150 μM NCTD. The HK-2 cells exhibited a reduction in intracellular ROS and an increase in mitochondrial membrane potential (ΔψM) upon exposure to C60-modified micelles compared to the NCTD group.

conclusionsThe DSPE-PEG-C60/NCTD micelles, as prepared in this study, demonstrated the ability to decrease cytotoxicity and ROS levels in normal renal cells (HK-2) in vitro. Additionally, these micelles showed an enhanced antitumor activity against human hepatocellular carcinoma cells (HepG2, BEL-7402).

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsApoptosisBridged Bicyclo Compounds, HeterocyclicCell Line, TumorHumansMicellesReactive Oxygen SpeciesBridged Bicyclo Compounds, HeterocyclicMicellesnorcantharidinReactive Oxygen SpeciesattenuateC60hepatic carcinomananomicellesnorcantharidin

Identifiers

PMID38005331
PMCPMC10673410
OpenAlexW4388733148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.